Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1. (Previously Cancelled on 8/8/02)
2. (Previously Cancelled on 9/28/00)
3. (Previously Cancelled on 11/12/01)
4. (Previously Cancelled on 8/8/02)
5. (Previously Cancelled on 8/8/02)
6. (Previously Cancelled on 11/12/01)
7. (Previously Cancelled on 11/12/01)
8. (Previously Cancelled on 11/12/01)
9. (Previously Cancelled on 9/28/00)
10. (Previously Cancelled on 9/28/00)
11. (Previously Cancelled on 8/8/02)
12. (Previously Cancelled on 11/12/01)
13. (Previously Cancelled on 8/8/02)
14. (Previously Cancelled on 8/8/02)
15. (Previously Cancelled on 11/12/01)
16. (Previously Cancelled on 9/28/00)
17. (Previously Cancelled on 9/28/00)
18. (Previously Cancelled on 9/28/00)
19. (Previously Cancelled on 9/28/00)
20. (Previously Cancelled on 8/8/02)
21. (Previously Cancelled on 8/8/02)
22. (Previously Cancelled on 11/12/01)
23. (Previously Cancelled on 11/12/01)
24. (Previously Cancelled on 11/12/01)

25. (Previously Cancelled on 11/12/01)

26. (Previously Cancelled on 11/12/01)

27. (Previously Cancelled on 11/12/01)

28. (Previously Cancelled on 11/12/01)

29. (Previously Cancelled on 11/12/01)

30. (Previously Cancelled on 11/12/01)

31. (Previously Cancelled on 8/8/02)

32. (Cancelled) A therapeutic mammalian non-plasmocyte cell genetically modified with a nucleic acid sequence, wherein the nucleic acid sequence comprises a nucleotide sequence coding for a therapeutic antibody:

    a. wherein the nucleotide sequence coding for the antibody is operably linked to a promoter for expressing the nucleotide sequence encoding the antibody in the mammalian non-plasmocyte cell;

    b. wherein the nucleotide sequence encoding the antibody is not modified;

    c. wherein the nucleotide sequence comprises a sequence for termination of the transcription, situated downstream from the sequence coding for the antibody; and

    d. wherein the antibody is secreted into the blood circulation of a host mammal after the implantation of the mammalian non-plasmocyte cell into the host mammal.

33. (Previously Cancelled on 5/29/03)

34. (Previously Cancelled on 5/29/03)

35. (Cancelled) The therapeutic cell of claim 32, wherein the cell is selected from the group consisting of: keratinocyte, hepatocyte, fibroblast, myoblast, endothelial cell, and hematopoetic cell.

36. (Cancelled) The therapeutic cell of claim 32, wherein the antibody is directed against a tumor cell antigen.

37. (Cancelled) The therapeutic cell of claim 32, wherein the antibody is directed against a virus.

38. (Cancelled) A method of making a therapeutic mammalian non-plasmocyte cell comprising a nucleic acid sequence further comprising a polynucleotide coding for a therapeutic antibody, comprising the step of transferring upon transfection at least one nucleic acid sequence comprising a polynucleotide coding for the therapeutic antibody:

a. wherein the coding polynucleotide is operably linked to a promoter for expressing the polynucleotide encoding the antibody in the mammalian non-plasmocyte cell;

b. wherein the polynucleotide sequence encoding the antibody is not modified; and

c. wherein translation of the coding polynucleotide results in the secretion of the antibody from the mammalian non-plasmocyte cell into the blood circulation of a host mammal after the implantation of the mammalian non-plasmocyte cell.

39. (Cancelled) The cell of claim 32, wherein the vector is a viral vector.

40. (Cancelled) A method of making a mammalian non-plasmocyte cell comprising a nucleic acid containing a polynucleotide coding for a native unmodified antibody polypeptide comprising the step of transferring, upon transfection, at least one nucleic acid comprising a polynucleotide coding for said native, unmodified antibody polypeptide,

a. wherein the coding polynucleotide is operably linked to a promoter for expressing the polynucleotide encoding the antibody polypeptide in a mammalian non-plasmocyte cell; and

b. wherein the coding polynucleotide is operably linked to a polynucleotide element required for the secretion of the antibody polypeptide from the mammalian non-plasmocyte cell into the blood circulation of a host mammal after the implantation of the mammalian non-plasmocyte cell.

41. (Previously Cancelled on 5/29/03)

42. (Cancelled) A method for delivering an antibody molecule to the blood system of a host mammal, comprising: implanting a therapeutic cell into a mammal;

a. wherein the implanted cell is a mammalian non-plasmocyte cell genetically modified with a nucleic acid sequence, wherein the nucleic acid sequence comprises a nucleotide sequence coding for a therapeutic antibody molecule;

b. wherein the nucleotide sequence coding for the therapeutic antibody molecule is operably linked to a promoter for expressing the nucleotide sequence coding the therapeutic antibody in the mammalian non-plasmocyte cell;

c. wherein the nucleotide sequence encoding the antibody molecule is not modified;

d. wherein the nucleic acid comprises a sequence for termination of the transcription, situated downstream from the sequence coding for a therapeutic antibody molecule; and

e. wherein translation of the nucleotide sequence results in the secretion of the therapeutic antibody molecule from the mammalian non-plasmocyte cell into the blood circulation of a host mammal after the implantation of the mammalian non-plasmocyte cell into the host mammal.

43. (Cancelled) The method of claim 42, wherein the therapeutic antibody molecule is selected from the group consisting of: a single antibody heavy chain, a single antibody light chain, and an antibody molecule comprising a heavy chain and a light chain, or fragments thereof.

44. (New) A genetically modified cell comprising, a polynucleotide encoding an antibody or fragment thereof, and a promoter sequence controlling expression of the polynucleotide in the cell, wherein the cell expresses and secretes the antibody or fragments thereof, and wherein the cell is a non-plasmocyte mammalian cell suitable for introduction into a subject in that the genetically modified cell does not cause disease in the subject following transplantation.

45. (New) The genetically modified cell of claim 44, wherein the cell is selected from the group consisting of keratinocytes, hepatocytes, skin fibroblasts, myoblasts, endothelial cells and hematopoietic stem cells.

46. (New) The genetically modified cell of claim 44, wherein the cell is a C2C12 myoblast cell.

47. (New) The genetically modified cell of claim 44, wherein the cell is capable of differentiating into a tissue but retains the ability to express the antibody.

48. (New) The genetically modified cell of claim 44, wherein the antibody is secreted into the blood of a subject mammal having received the cell.

49. (New) The genetically modified cell of claim 44, wherein the antibody is detectable in the blood of the subject mammal following transplant of the cell.

50. (New) The genetically modified cell of claim 44, wherein the antibody is detectable in the blood of the subject mammal for at least four months following transplant of the cell.

51. (New) The genetically modified cell of claim 44, wherein the antibody is secreted into the blood of a subject mammal having received the cell, and the antibody is detectable in the blood of the subject mammal at a concentration exceeding 100 ng/ml of serum.

52. (New) A method of delivering an antibody to a subject comprising, obtaining a genetically modified cell further comprising a polynucleotide encoding an antibody or fragment thereof, and a promoter sequence controlling expression of the polynucleotide in the cell, wherein the cell expresses and secretes the antibody or fragments thereof, and transplanting the genetically modified cell into the subject, wherein the cell is a non-plasmocyte mammalian cell suitable for introduction into a subject in that the genetically modified cell does not cause disease in the subject following transplantation.

53. (New) The method of claim 52, wherein the cell is selected from the group consisting of keratinocytes, hepatocytes, skin fibroblasts, myoblasts, endothelial cells and hematopoietic stem cells.

54. (New) The method of claim 52, wherein the cell is a C2C12 myoblast cell.

55. (New) The method of claim 52, wherein the cell is capable of differentiating into a tissue but retains the ability to express the antibody.

56. (New) The method of claim 52, wherein the antibody is secreted into the blood of a subject mammal having received the cell.

57. (New) The method of claim 52, wherein the antibody is detectable in the blood of the subject mammal following transplant of the cell.

58. (New) The method of claim 52, wherein the antibody is detectable in the blood of the subject mammal for at least four months following transplant of the cell.

59. (New) The method of claim 52, wherein the antibody is secreted into the blood of a subject mammal having received the cell, and the antibody is detectable in the blood of the subject mammal at a concentration exceeding 100 ng/ml of serum.